Testing a three-drug combination to prevent blood cancer from returning

Plain-English translation of NCT07148180 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new combination of three medications — , azacitidine, and — to see if they can safely treat patients with acute myeloid leukemia (AML) who still have residual disease (leftover leukemia cells that doctors cannot see). Two of these medications (azacitidine and ) are already FDA-approved for AML, but this is the first time researchers are testing all three together for this purpose.

Even after successful treatment, patients with AML can have tiny amounts of leukemia cells left in their bone marrow that are invisible to the naked eye but can cause the disease to return. This study exists to find out if this new three-drug combination can safely eliminate these hidden cancer cells and prevent relapse.

Do you qualify?

You likely qualify if…

you are 18 years of age or older
you have been diagnosed with acute myeloid leukemia (including new cases, secondary AML, or AML that developed from an earlier blood condition called MDS)
your leukemia is currently in remission or near-remission with very few visible leukemia cells in your bone marrow
you have measurable amounts of residual disease detectable by special laboratory tests
your heart, liver, and kidney function are adequate to safely receive the treatment
you are willing to commit to about 4 years of study visits and follow-up care

You likely don't qualify if…

you have received prior treatment with other CD123-targeted therapies
you have a history of acute promyelocytic leukemia (a specific subtype of AML)
you received intensive chemotherapy within the past 2 weeks
you have a history of a previous stem cell transplant
you have uncontrolled severe lung disease that could put you at serious risk during the study

What participation looks like

Participants will visit the clinic regularly over about 4 years to receive the three medications in 28-day cycles. During the first two cycles, you will take azacitidine by mouth for 7 days, for 3 days (days 4–6), and on days 1 and 14 of each cycle. You will have frequent blood tests, bone marrow biopsies, and imaging scans (CT, MRI, or PET) to monitor how well the treatment is working and check for side effects. The study will help researchers determine the safest and most effective dose of the medication combination.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Testing a three-drug combination to prevent blood cancer from returning

What is this trial?

Do you qualify?

What participation looks like

Trial locations